

Drugs

Biogen, which is licensing Spinraza [a drug for spinal muscular atrophy] from Ionis Pharmaceuticals, said this week that one dose will have a list price of \$125,000. That means the drug will cost \$625,000 to \$750,000 to cover the five or six doses needed in the first year, and about \$375,000 annually after that to cover the necessary three doses a year. Patients will presumably take Spinraza for the rest of their lives.

New York Times, December 31, 2016